Open AccessFecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease
Author(s) -
Yeoun Joo Lee,
Jae Hong Park
Publication year - 2022
Publication title -
pediatric gastroenterology, hepatology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.44
H-Index - 19
eISSN - 2234-8646
pISSN - 2234-8840
DOI - 10.5223/pghn.2022.25.5.396
Subject(s) - calprotectin , medicine , gastroenterology , stage (stratigraphy) , receiver operating characteristic , crohn's disease , surrogate endpoint , prednisolone , area under the curve , inflammatory bowel disease , disease , paleontology , biology
This study evaluated the predictive role of fecal calprotectin (FC) measured at an early stage of treatment for monitoring clinical remission (CR) after six months and endoscopic remission (ER) after one year of treatment in pediatric Crohn's disease (CD).